Skip to content
OpenCapital
Get started

Adaptive Biotechnologies ADPT EV / sales

EV / sales at other companies

Guardant Health logo
Guardant HealthGH
11.8×+4.3×
Natera, Inc. logo
Natera, Inc.NTRA
11×+1.0×
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
27.8×+26.3×
GeneDx Holdings logo
GeneDx HoldingsWGS
4.3×-3.1×
Veracyte logo
VeracyteVCYT
4.3×-0.4×
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
22.7×+2.8×

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$2.76B+93.6%
Enterprise value$2.89B+78.0%
P/S9.3×+1.8×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity1×-0.2×
Current ratio3.4×+0.4×

Where this comes from

Calculated from Adaptive Biotechnologies’s reported figures.

enterprise value/total revenue=7.7×

Based on the most recent quarter.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's EV / sales?
Adaptive Biotechnologies (ADPT) reported EV / sales of 7.7× in Q1 2026.
How has Adaptive Biotechnologies's EV / sales changed year-over-year?
Adaptive Biotechnologies's EV / sales increased by 14.2% year-over-year, from 6.7× to 7.7×.
What is the long-term trend for Adaptive Biotechnologies's EV / sales?
Over 5 years (2020 to 2025), Adaptive Biotechnologies's EV / sales has grown at a -35.5% compound annual growth rate (CAGR), from 84.7× to 9.5×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.